CJC-1295 without DAC (Mod GRF 1-29)
ProtocolFor protocol designers building CJC-1295 without DAC (Mod GRF 1-29) into a multi-compound regimen, the practical questions are pharmacokinetic compatibility, route compatibility, receptor non-overlap, and operational scheduling around real-world constraints (travel, meals, training). The 100 mcg 1-3x daily subq dose at ~30 min half-life informs which scheduling pattern fits.
Key Takeaways
Scheduling lens: CJC-1295 without DAC (Mod GRF 1-29)'s ~30 min half-life via subq places it in the multi-daily-dosing bucket. Mechanism: Same GHRH-receptor agonism as DAC variant. Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset. Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering. Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.
Same GHRH-receptor agonism as DAC variant. Four amino acid substitutions resist enzymatic cleavage. Without the albumin-binding tail, the molecule clears in roughly half an hour — useful for evening dosing that mimics natural sleep-time GH pulse. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for CJC-1295 without DAC (Mod GRF 1-29).
Stack scheduling with other compounds
When CJC-1295 without DAC (Mod GRF 1-29) is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Multiple subcutaneous compounds can be combined in a single injection where compatible, or staggered through the day where pharmacokinetics differ meaningfully. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.
Cycle length and off-cycle planning
Standard CJC-1295 without DAC (Mod GRF 1-29) cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.
Daily and weekly timing
CJC-1295 without DAC (Mod GRF 1-29) with a ~30 min half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1-3x daily SubQ, with consistency mattering more than the absolute clock time of any single dose.
The most-asked scheduling question for CJC-1295 without DAC (Mod GRF 1-29) in wash-out is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
For cycle length scheduling, CJC-1295 without DAC (Mod GRF 1-29) is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
Schedule design for CJC-1295 without DAC (Mod GRF 1-29) in tapered cycles starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
The most-asked scheduling question for CJC-1295 without DAC (Mod GRF 1-29) in multi-peptide timing is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 100 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 60 mcg | 4–6 weeks initial cycle |
| Protocol focus | SubQ | 100 mcg | 1-3x daily SubQ |
| Maintenance phase | SubQ | 70 mcg | Ongoing with periodic pauses |
Dose timing for CJC-1295 without DAC (Mod GRF 1-29) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
CJC-1295 without DAC (Mod GRF 1-29) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.
- CJC-1295 without DAC (Mod GRF 1-29) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in protocol / scheduling / cycling protocols.
- CJC-1295 without DAC (Mod GRF 1-29) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in protocol / scheduling / cycling protocols.
- CJC-1295 without DAC (Mod GRF 1-29) + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in protocol / scheduling / cycling protocols.
- CJC-1295 without DAC (Mod GRF 1-29) + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with CJC-1295 without DAC (Mod GRF 1-29)'s mechanism in protocol / scheduling / cycling protocols.
Short half-life produces fewer sustained-IGF-1 concerns than DAC variant. Site reactions common. Stack with ipamorelin for synergy.
Lens-specific safety considerations for protocol / scheduling / cycling use of CJC-1295 without DAC (Mod GRF 1-29): Short half-life produces fewer sustained-IGF-1 concerns than DAC variant. Site reactions common. Stack with ipamorelin for synergy. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| CJC-1295 without DAC (Mod GRF 1-29) | Short-acting GHRH analogue | ~30 min | Protocol |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
Best practice for re-cycling?
When to integrate CJC-1295 without DAC (Mod GRF 1-29) into an existing stack?
Cycle length and off-cycle period?
Daily timing for CJC-1295 without DAC (Mod GRF 1-29)?
What route should I use for CJC-1295 without DAC (Mod GRF 1-29)?
What does CJC-1295 without DAC (Mod GRF 1-29) stack well with?
Start a CJC-1295 without DAC (Mod GRF 1-29) Protocol
Alukard provides physician-supervised peptide protocols with GMP-certified CJC-1295 without DAC (Mod GRF 1-29) and GMP-certified compounds with personalised cycle design.
Get ProtocolQuick Facts
- Molecular weight
- ~3367 Da
- Sequence length
- 29 aa
- Half-life
- ~30 min
- WADA
- Banned (S2 class)
- FDA
- Unapproved
- Research
- Mechanistic studies; off-label use widespread
Stack Partners
All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 without DAC (Mod GRF 1-29) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Protocol / Scheduling / Cycling Protocol for CJC-1295 without DAC (Mod GRF 1-29)
Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.
HIPAA Compliant · GMP Certified · Physician Supervised